.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SURMOUNT-1 evaluated once-weekly tirzepatide in adults with obesity or overweight and without diabetes. Across the studied doses, tirzepatide produced large reductions in body weight compared with placebo over 72 weeks, with a substantial proportion of participants achieving weight-loss thresholds of 15%, 20% or more. The study helped establish dual GIP/GLP-1 receptor agonism as a major new approach to obesity pharmacotherapy. For internists, the practical implication is that obesity treatment can now include highly effective incretin-based medicines, but selection should remain individualized. Dose escalation, gastrointestinal tolerability, treatment cost and long-term adherence affect real-world success. The trial also reinforces that pharmacotherapy works best as part of comprehensive obesity care rather than as a stand-alone intervention. Patients should be assessed for hypertension, sleep apnea, diabetes, fatty liver disease and cardiovascular risk, because meaningful weight loss may influence multiple comorbidities. The central clinical task is not simply prescribing a potent drug but building a sustainable chronic-disease plan around it.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SURMOUNT-1 evaluated once-weekly tirzepatide in adults with obesity or overweight and without diabetes. Across the studied doses, tirzepatide produced large reductions in body weight compared with placebo over 72 weeks, with a substantial proportion of participants achieving weight-loss thresholds of 15%, 20% or more. The study helped establish dual GIP/GLP-1 receptor agonism as a major new approach to obesity pharmacotherapy. For internists, the practical implication is that obesity treatment can now include highly effective incretin-based medicines, but selection should remain individualized. Dose escalation, gastrointestinal tolerability, treatment cost and long-term adherence affect real-world success. The trial also reinforces that pharmacotherapy works best as part of comprehensive obesity care rather than as a stand-alone intervention. Patients should be assessed for hypertension, sleep apnea, diabetes, fatty liver disease and cardiovascular risk, because meaningful weight loss may influence multiple comorbidities. The central clinical task is not simply prescribing a potent drug but building a sustainable chronic-disease plan around it.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
